RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements

A Peyman; V Wehner; J Knolle; H U Stilz; G Breipohl; K H Scheunemann; D Carniato; J M Ruxer; J F Gourvest; T R Gadek; S Bodary

doi:10.1016/s0960-894x(99)00661-7

RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements

Bioorg Med Chem Lett. 2000 Jan 17;10(2):179-82. doi: 10.1016/s0960-894x(99)00661-7.

Authors

A Peyman¹, V Wehner, J Knolle, H U Stilz, G Breipohl, K H Scheunemann, D Carniato, J M Ruxer, J F Gourvest, T R Gadek, S Bodary

Affiliation

¹ Hoechst Marion Roussel Deutschland GmhH, Frankfurt, Germany. anusch.peyman@hmrag.com

PMID: 10673106
DOI: 10.1016/s0960-894x(99)00661-7

Abstract

The synthesis of a series of RGD mimetic alpha(v)beta3 antagonists containing a hydantoin scaffold is shown. The results demonstrate some of the structural requirements for the design of selective alpha(v)beta3 antagonists (vs alpha(IIb)beta3) in terms of the Arg-mimetic, the distance between N- and C-terminus and the lipophilic side chain.

MeSH terms

Fibrinogen / metabolism
Humans
Hydantoins / chemical synthesis*
Imidazoles / chemical synthesis
Molecular Structure
Oligopeptides / chemical synthesis*
Peptides / metabolism
Platelet Glycoprotein GPIIb-IIIa Complex / metabolism
Protein Binding / drug effects
Receptors, Vitronectin / antagonists & inhibitors

Substances

Hydantoins
Imidazoles
Oligopeptides
Peptides
Platelet Glycoprotein GPIIb-IIIa Complex
Receptors, Vitronectin
arginyl-glycyl-aspartic acid
kistrin
Fibrinogen